Cost-effectiveness and potential budget impact of non-pharmacological interventions for early management in prehypertensive people: an economic evaluation for China.

Liang, Leyi; Shao, Taihang; Li, Hao; Zhao, Mingye; Tang, Wenxi

Liang, Leyi; Shao, Taihang; Li, Hao; Zhao, Mingye; Tang, Wenxi.

Afiliação

Liang L; Center for Pharmacoeconomics and Outcomes Research, China Pharmaceutical University, Nanjing, 211198, China.
Shao T; Center for Pharmacoeconomics and Outcomes Research, China Pharmaceutical University, Nanjing, 211198, China.
Li H; Center for Pharmacoeconomics and Outcomes Research, China Pharmaceutical University, Nanjing, 211198, China.
Zhao M; Center for Pharmacoeconomics and Outcomes Research, China Pharmaceutical University, Nanjing, 211198, China.
Tang W; Center for Pharmacoeconomics and Outcomes Research, China Pharmaceutical University, Nanjing, 211198, China. tokammy@cpu.edu.cn.

BMC Public Health ; 23(1): 1531, 2023 08 11.

Article em En | MEDLINE | ID: mdl-37568086

Assuntos

Hipertensão; Humanos; Análise Custo-Benefício; Doença Crônica; Hipertensão/terapia; Orçamentos; China

Palavras-chave

Budget impact analysis; China; Cost-effectiveness analysis; Early management; Non-pharmacological intervention; Prehypertension

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hipertensão Tipo de estudo: Health_economic_evaluation / Prognostic_studies Limite: Humans País/Região como assunto: Asia Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google